Previously, we have shown that different cancer‐causing mutations affect conformational changes of one of the most frequently mutated kinases in melanoma, the oncokinase BRAF.33 In this proof of principle study we showed evidence that the effectiveness of FDA‐approved drugs targeting different BRAF kinase‐mutants can be anticipated. This evidence concerns the gene BRAF and melanoma.